UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/555,583	10/16/2006	Wolfgang Sohngen	09498.0017	4402
	52 7590 02/24/2009 NNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER		EXAMINER	
LLP			SWOPE, SHERIDAN	
	901 NEW YORK AVENUE, NW WASHINGTON, DC 20001-4413		ART UNIT	PAPER NUMBER
			1652	
			MAIL DATE	DELIVERY MODE
			02/24/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)
	10/555,583	SOHNGEN, WOLFGANG
Office Action Summary	Examiner	Art Unit
	SHERIDAN SWOPE	1652
The MAILING DATE of this communication ap Period for Reply	pears on the cover sheet with the o	correspondence address
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING D. - Extensions of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period. - Failure to reply within the set or extended period for reply will, by statut Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICATION 136(a). In no event, however, may a reply be tir will apply and will expire SIX (6) MONTHS from e, cause the application to become ABANDONE	N. mely filed the mailing date of this communication. ED (35 U.S.C. § 133).
Status		
Responsive to communication(s) filed on 16 A This action is FINAL . 2b) ☑ This Since this application is in condition for allowed closed in accordance with the practice under the second seco	s action is non-final. ance except for formal matters, pro	
Disposition of Claims		
4) Claim(s) <u>12-29</u> is/are pending in the application 4a) Of the above claim(s) is/are withdrases 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) <u>12-29</u> are subject to restriction and/or	awn from consideration.	
Application Papers		
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) acceptable and applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the E	cepted or b) objected to by the drawing(s) be held in abeyance. Section is required if the drawing(s) is ob	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documen 2. Certified copies of the priority documen 3. Copies of the certified copies of the priority application from the International Burea * See the attached detailed Office action for a list	ts have been received. ts have been received in Applicat prity documents have been receive nu (PCT Rule 17.2(a)).	ion No ed in this National Stage
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail D 5) Notice of Informal F 6) Other:	ate

Application/Control Number: 10/555,583 Page 2

Art Unit: 1652

DETAILED ACTION

Claims 12-29 are pending.

Election/Restrictions

Restriction is required under 35 U.S.C. 121.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, Claims 12-22, drawn to a method of treating depression or anxiety using an inhibitor of t-PA-mediated activation of a glutamate receptor.

Group II, Claims 23-24, drawn to a method of treating stroke using DSPA and a thrombolytic.

Group III, Claims 25-29, drawn to a method for providing neuroprotection using DSPA.

For each of Inventions I-III above, restriction to one of the following is also required under 35 USC 121. Therefore, election is required of one of Inventions I-III and one or more of Inventions (A)-(L), as indicated.

If Group I is elected, elect one of:

- (A) Depression
- (B) Anxiety

If Group I is elected, elect one of:

- (C) An NMDA receptor
- (D) A non-NMDA receptor

If Group I is elected, elect one of:

- (E) Not a protease inhibitor
- (F) A protease inhibitor

If (F) is elected, elect one of:

- (i) A non-serine protease inhibitor
- (ii) A serine protease inhibitor
- If (ii) is elected, elect one of the inhibitors listed in Claim 16

Application/Control Number: 10/555,583 Page 3

Art Unit: 1652

(G) A plasminogen activator

If (G) is elected, elect one of:

- (i) Not DSPA
- (ii) DSPA

If (ii) is elected, elect one of:

- (a) Not SEQ ID NO: 1
- (b) SEQ ID NO: 1

If Group II is elected, elect one of:

- (H) Not t-PA
- (I) t-PA

If Group III is elected, elect one of:

(J) One of the conditions listing in Claim 26

If Group III is elected, also elect one of:

- (K) Not SEQ ID NO: 1
- (L) SEQ ID NO: 1

The inventions listed as Groups I-III do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical feature for the following reasons.

The technical feature linking Groups I-III appears to be that they all relate to methods of treatment using a t-PA modulator. However, methods of treatment using a t-PA modulator were known in the art. Moreover, as evidenced by Grandjean et al, 2004, Schleuning et al, 2001 teach a method of treating stroke in humans using DSPA (pg 121), which anticipates Claim 23.

Therefore Groups I-III share no special technical feature as defined by PCT Rule 13.2, as it does not define a contribution over the prior art. Furthermore, the methods of Groups I-II(A)-(L) do not use the same reagents or produce the same results. Accordingly, Groups I-III are not so linked by the same or a corresponding special technical feature as to form a single general inventive concept.

Applicant is advised that the reply to this requirement to be complete <u>must</u> include (i) an election of an invention and sub-invention(s) to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse. Traversal must be presented at the time of election in order to be considered timely. Failure to timely traverse the requirement will result in the loss of right to petition under 37 CFR 1.144. If claims are added after the election, applicant must indicate which of these claims are readable on the elected invention.

Should Applicants traverse on the ground that the inventions are not patentably distinct, Applicants should submit evidence or identify such evidence now of record showing the inventions to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

To insure that each document is properly filed in the electronic file wrapper, it is requested that each of amendments to the specification, amendments to the claims, Applicants' remarks, requests for extension of time, and any other distinct papers be submitted on separate pages.

It is also requested that Applicants identify support, within the original application, for any amendments to the claims and specification.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sheridan L. Swope whose telephone number is 571-272-0943. The examiner can normally be reached on M-F; 9:30-7 EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Nashed can be reached on 571-272-0934. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published application may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on the access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/SHERIDAN SWOPE/ Primary Examiner, Art Unit 1652